1995•SynapseRequires access

Repeated quinpirole treatment: Locomotor activity, dopamine synthesis, and effects of selective dopamine antagonists

James K. Rowlett, Bruce A. Mattingly, Michael Thomas Bardo

Open publisher page 38 citations

Abstract

Abstract Repeated treatment with the non‐selective dopamine agonist apomorphine results in behavioral sensitization and enhanced dopamine synthesis in dopamine projection fields. To examine the role of D2‐type dopamine receptors in modulating these effects, the present experiment assessed the effects of repeated treatment with the D2‐type agonist quinpirole on locomotor activity and dopamine synthesis. In the first experiment, rats were treated with vehicle or one of two doses (0.3 or 3.0 mg/kg) of quinpirole for 8 days. Daily measures of locomotor activity revealed an initial suppression of activity produced by quinpirole which dissipated over the 8 days of treatment. A trend for an increase in activity for 3.0 mg/kg quinpirole compared to vehicle was obtained on day 8. Twenty‐four hours after cessation of treatment, dopamine synthesis, measured as accumulation of 3,4‐dihydroxyphenylalanine (DOPA) after treatment with the DOPA decarboxylase inhibitor NSD‐1015, was enhanced in the striatum, but not nucleus accumbensolfactory tubercle (NAOT) or ventral mesencephalon (VM). In Experiment 2, rats were treated for 8 days with vehicle, 3.0 mg/kg quinpirole or the D1 antagonist SCH 23390 (0.5 mg/kg) in a two (vehicle or quinpirole) × two (vehicle or SCH 23390) design. Quinpirolealone treatment resulted in a reduction of the locomotor suppressant effects of the drug. SCH 23390‐alone and quinpirole‐SCH 23390 combined treatment resulted in decreased activity compared to the vehicle control group that did not change across days. DOPA accumulation was enhanced in the striatum and NAOT after quinpirole treatment; however, SCH 23390 had no effect. In Experiment 3, rats were treated for 10 days with vehicle, 3.0 mg/kg quinpirole or the D2 antagonist eticlopride (1.0 mg/kg) in a two (vehicle or quinpirole) × two (vehicle or eticlopride) design. As in the first two experiments, repeated quinpirolealone treatment resulted in a reduction of the locomotor suppressant effects of the drug; however, locomotor activity in this group was enhanced compared to vehicle controls on day 10. Eticlopridealone and eticlopride‐quinpirole treated rats had suppressed locomotor activity across the 10 days. DOPA accumulation was enhanced by both repeated quinpirole and repeated eticlopride treatment in the striatum and NAOT. DOPA accumulation in eticlopride‐quinpirole treated rats was not different from vehicle control levels in the NAOT, while no significant difference was obtained between the eticlopridealone and eticlopride‐quinpirole groups in the striatum. The locomotor activity data suggest that repeated quinpirole treatment results in tolerance to the locomotor suppressant effect of the drug. Evidence for sensitization was obtained in two out of three of the experiments. These results suggest that enhanced dopamine synthesis after repeated non‐selective dopamine agonist treatment is modulated by D2‐type dopamine receptors. © 1995 Wiley‐Liss, Inc.

About this research paper

What this paper is about

Abstract Repeated treatment with the non‐selective dopamine agonist apomorphine results in behavioral sensitization and enhanced dopamine synthesis in dopamine projection fields. To examine the role of D2‐type dopamine receptors in modulating these effects, the present experiment assessed the effects of repeated treatment with the D2‐type agonist quinpirole on locomotor activity and dopamine synthesis. In the first experiment, rats were treated with vehicle or one of two doses (0.3 or 3.0 mg/kg) of quinpirole for 8 days. Daily measures of locomotor activity revealed an initial suppression of activity produced by quinpirole which dissipated over the 8 days of treatment. A trend for an increase in activity for 3.0 mg/kg quinpirole compared to vehicle was obtained on day 8. Twenty‐four hours after cessation of treatment, dopamine synthesis, measured as accumulation of 3,4‐dihydroxyphenylalanine (DOPA) after treatment with the DOPA decarboxylase inhibitor NSD‐1015, was enhanced in the striatum, but not nucleus accumbensolfactory tubercle (NAOT) or ventral mesencephalon (VM). In Experiment 2, rats were treated for 8 days with vehicle, 3.0 mg/kg quinpirole or the D1 antagonist SCH 23390 (0.5 mg/kg) in a two (vehicle or quinpirole) × two (vehicle or SCH 23390) design. Quinpirolealone treatment resulted in a reduction of the locomotor suppressant effects of the drug. SCH 23390‐alone and quinpirole‐SCH 23390 combined treatment resulted in decreased activity compared to the vehicle control group that did not change across days. DOPA accumulation was enhanced in the striatum and NAOT after quinpirole treatment; however, SCH 23390 had no effect. In Experiment 3, rats were treated for 10 days with vehicle, 3.0 mg/kg quinpirole or the D2 antagonist eticlopride (1.0 mg/kg) in a two (vehicle or quinpirole) × two (vehicle or eticlopride) design. As in the first two experiments, repeated quinpirolealone treatment resulted in a reduction of the locomotor suppressant effects of the drug; however, locomotor activity in this group was enhanced compared to vehicle controls on day 10. Eticlopridealone and eticlopride‐quinpirole treated rats had suppressed locomotor activity across the 10 days. DOPA accumulation was enhanced by both repeated quinpirole and repeated eticlopride treatment in the striatum and NAOT. DOPA accumulation in eticlopride‐quinpirole treated rats was not different from vehicle control levels in the NAOT, while no significant difference was obtained between the eticlopridealone and eticlopride‐quinpirole groups in the striatum. The locomotor activity data suggest that repeated quinpirole treatment results in tolerance to the locomotor suppressant effect of the drug. Evidence for sensitization was obtained in two out of three of the experiments. These results suggest that enhanced dopamine synthesis after repeated non‐selective dopamine agonist treatment is modulated by D2‐type dopamine receptors. © 1995 Wiley‐Liss, Inc.

Why it matters

OpenAlex reports 38 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Abstract Repeated treatment with the non‐selective dopamine agonist apomorphine results in behavioral sensitization and enhanced dopamine synthesis in dopamine projection fields. To examine the role of D2‐type dopamine receptors in modulating these effects, the present experiment assessed the effects of repeated treatment with the D2‐type agonist quinpirole on locomotor activity and dopamine synthesis. In the first experiment, rats were treated with vehicle or one of two doses (0.3 or 3.0 mg/kg) of quinpirole for 8 days. Daily measures of locomotor activity revealed an initial suppression of activity produced by quinpirole which dissipated over the 8 days of treatment. A trend for an increase in activity for 3.0 mg/kg quinpirole compared to vehicle was obtained on day 8. Twenty‐four hours after cessation of treatment, dopamine synthesis, measured as accumulation of 3,4‐dihydroxyphenylalanine (DOPA) after treatment with the DOPA decarboxylase inhibitor NSD‐1015, was enhanced in the striatum, but not nucleus accumbensolfactory tubercle (NAOT) or ventral mesencephalon (VM). In Experiment 2, rats were treated for 8 days with vehicle, 3.0 mg/kg quinpirole or the D1 antagonist SCH 23390 (0.5 mg/kg) in a two (vehicle or quinpirole) × two (vehicle or SCH 23390) design. Quinpirolealone treatment resulted in a reduction of the locomotor suppressant effects of the drug. SCH 23390‐alone and quinpirole‐SCH 23390 combined treatment resulted in decreased activity compared to the vehicle control group that did not change across days. DOPA accumulation was enhanced in the striatum and NAOT after quinpirole treatment; however, SCH 23390 had no effect. In Experiment 3, rats were treated for 10 days with vehicle, 3.0 mg/kg quinpirole or the D2 antagonist eticlopride (1.0 mg/kg) in a two (vehicle or quinpirole) × two (vehicle or eticlopride) design. As in the first two experiments, repeated quinpirolealone treatment resulted in a reduction of the locomotor suppressant effects of the drug; however, locomotor activity in this group was enhanced compared to vehicle controls on day 10. Eticlopridealone and eticlopride‐quinpirole treated rats had suppressed locomotor activity across the 10 days. DOPA accumulation was enhanced by both repeated quinpirole and repeated eticlopride treatment in the striatum and NAOT. DOPA accumulation in eticlopride‐quinpirole treated rats was not different from vehicle control levels in the NAOT, while no significant difference was obtained between the eticlopridealone and eticlopride‐quinpirole groups in the striatum. The locomotor activity data suggest that repeated quinpirole treatment results in tolerance to the locomotor suppressant effect of the drug. Evidence for sensitization was obtained in two out of three of the experiments. These results suggest that enhanced dopamine synthesis after repeated non‐selective dopamine agonist treatment is modulated by D2‐type dopamine receptors. © 1995 Wiley‐Liss, Inc.

Key concepts: Quinpirole, Dopamine, Dopamine agonist, Agonist, Chemistry, SCH-23390, Apomorphine, Nucleus accumbens

Related papers

Back to paper searchBrowse research topicsOriginal source
Repeated quinpirole treatment: Locomotor activity, dopamine synthesis, and effects of selective dopamine antagonists — Research Paper | ScholarLens